Project Grant R21AI191013

Award Date 5/1/25
Completion Date 4/30/27
Dollars Obligated $221K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Arkansas, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,747,795 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Regents of the University of Minnesota to develop novel antiviral therapies against the monkeypox (MPXV) virus. The project aims to further optimize and advance three promising antiviral hit compounds identified through the university's prior research, leveraging a multi-disciplinary approach spanning medicinal chemistry, virology,...
This $199,775 Project Grant from the National Science Foundation Division of Environmental Biology will support research at the University of California, Los Angeles to develop models to understand and predict the spread of monkeypox virus. The research will analyze monkeypox virus surveillance data and transmission patterns in both core and non-core populations. Mathematical models will be built to design disease control strategies, such as comparing outcomes from reducing transmission in...
This Project Grant award of $193,336 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund a study to assess factors associated with monkeypox (MPOX) vaccination, testing, and stigma among men who have sex with men (MSM) in the United States. The study aims to: 1) evaluate determinants and disparities of MPOX vaccination among MSM; 2) characterize differences in MPOX testing uptake among MSM...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $228,435 to the University of California, Irvine to study the role of the APOBEC3B enzyme in suppressing RNA virus infections. The research aims to identify novel APOBEC3B anti-viral functions that do not require its deaminase activity, focusing on how APOBEC3B modulates the PKR signaling pathway to promote translation...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $284,331 to the University of Massachusetts Medical School to study how naturally occurring viral infections may impact the stability and composition of gene therapy vectors based on adeno-associated virus (AAV). The research aims to develop novel methods to characterize the structure of AAV vector genomes as they...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is providing $856,769 to the Texas Biomedical Research Institute to study the role of APOBEC3 enzymes in mediating donor-specific immune responses to HIV/SIV. The key objectives are to integrate viral and host genetic datasets to identify the molecular determinants underlying variations in APOBEC3-induced mutations in...
This federal Project Grant award, totaling $206,801, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant funds research to improve understanding of the complex population dynamics that characterize chronic HIV infection. The key objectives are to: 1) develop a novel statistical phylogenetic tool (GOSIP) capable of identifying cooperative behavior through compensatory evolution, and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,447,376 to the University of Arkansas to conduct a comprehensive investigation into the dynamics of viruses in wild bat populations. The project aims to elucidate how bat behavior and virus shedding patterns shape spillover risk to humans and domestic animals. The research team will employ longitudinal monitoring,...
This $170,555 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant will fund research to investigate how ubiquitination, a process that attaches small regulatory proteins called ubiquitin to other proteins, affects the function of the Ebola virus protein VP35 and impacts the host immune response. The principal investigator plans to use biochemical and structural biology...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will use model RNA plant viruses to elucidate the mechanisms by which viruses modulate host chromatin dynamics and gene expression. The $892,050 award, spanning August 2024 to July 2027, will investigate how the P26 protein from Pea Enation Mosaic Virus 2 (PEMV2) undergoes liquid-liquid phase separation and partitions into...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $221,105.00 to the University of Arkansas for Medical Sciences (UAMS) to conduct research on the impact of host APOBEC3 enzymes on poxvirus diversification and evolution.

The research aims to investigate how APOBEC3 enzymes affect the genome of poxviruses, such as monkeypox, and to understand the mechanisms by which these viruses can undergo genetic changes that may enable them to evade host immune responses. The two-year project will involve in vitro biochemical analyses of APOBEC3 activity on poxvirus targets, as well as experimental evolution studies using vaccinia virus as a surrogate for monkeypox. The findings from this comprehensive investigation are intended to contribute knowledge that can be used to predict potential virus evolution trajectories and inform public health policies to better protect against emerging infectious threats.

Generated 5/13/25, 3:45 AM